Background and Aims Idiopathic noncirrhotic intrahepatic portal hypertension (NCIPH), a chronic microangiopathy of the liver caused by arsenicosis from use of contaminated groundwater, was reported from Asia. This study aimed to see, if in the twenty-first century, arsenicosis was present in NCIPH patients at our hospital and, if present, to look for groundwater contamination by arsenic in their residential locality. Methods Twenty-seven liver biopsy proven NCIPH patients, 25 portal hypertensive controls with hepatitis B or C related cirrhosis and 25 healthy controls, matched for residential locality, were studied. Eighty-four percent to 96 % of study subjects belonged to middle or lower socioeconomic category. Arsenicosis was looked for by estimation of arsenic levels in finger/toe nails and by skin examination. Arsenic levels in nails and in ground water (in NCIPH patients with arsenicosis) was estimated by mass spectrometry. Results Nail arsenic levels were raised in five (10 %) portal hypertensive study subjects [two NCIPH patients (both had skin arsenicosis) and three portal hypertensive controls]. All of these five patients were residents of West Bengal or Bangladesh. Skin arsenicosis was noted in three NCIPH patients (11 %) compared to none of disease/healthy controls. Ground water from residential locality of one NCIPH patient with arsenicosis (from Bangladesh) showed extremely high level of arsenic (79.5 μg/L). Conclusions Arsenicosis and microangiopathy of liver, possibly caused by environmental contamination continues in parts of Asia. Further studies are needed to understand the mechanisms of such 'poverty-linked thrombophilia'.
Introduction
Idiopathic noncirrhotic intrahepatic portal hypertension (NCIPH) is an important cause of portal hypertension at our centre [1, 2] . Noncirrhotic portal fibrosis is a histological subtype of the clinical entity, NCIPH, described commonly in India [3] [4] [5] [6] . NCIPH is characterized by a chronic microangiopathy of small intrahepatic portal vein radicles, suggesting that gut derived insults may be driving this disease [7] . We have reported higher prevalence of gut disorders in NCIPH patients in UK and in India (celiac disease in 14 % to 16 % of patients, ulcerative colitis in 9 %) [8, 9] . We have also documented low levels of plasma ADAMTS13 {a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13; a von Willebrand factor (vWF) cleaving protease}, despite well-compensated liver functions, and raised plasma vWF levels in NCIPH patients. ADAMTS13 to vWF imbalance may predispose to platelet-microthrombi formation in portal venules in response to gut derived insults-thus providing a mechanistic explanation for development of the isolated intrahepatic portal microangiopathy of NCIPH [10, 11] .
Chronic arsenic ingestion, from contaminated groundwater [12] , provides yet another example of gut derived insult driving NCIPH reported from various parts of India 1-5 decades ago [13] [14] [15] [16] . At biopsy, hepatic arsenic content was higher in patients with NCIPH than in those with cirrhosis [13] . In 1988, investigators from West Bengal reported 13 cases with noncirrhotic portal fibrosis which were associated to drinking of water contaminated with arsenic and also associated with high level of arsenic in liver tissue [16] . In a murine model, chronic arsenic ingestion caused significant hepatic fibrosis [17] . In contrast, from the West, arsenicosis causing NCIPH has been secondary to use of arsenic preparation (oral Fowler's solution) to treat psoriasis [18] [19] [20] .
We conducted this study to look for evidence of chronic arsenic toxicity in NCIPH patients and for evidence of groundwater arsenic contamination causing the same, in present day Indian subcontinent.
Methods
This hospital based case-control study was done to evaluate the association of arsenicosis with NCIPH. We compared patients with NCIPH (cases) to patients with hepatitis B/C related cirrhosis with portal hypertension (disease controls) and healthy controls. The study subjects were recruited after obtaining their informed consent for the study.
Recruitment of NCIPH cases and controls
NCIPH was diagnosed as per published criteria [21] , as follows: All NCIPH patients had esophageal or gastric varices (on endoscopy) with patent portal vein and hepatic venous outflow tract on Doppler ultrasound and an unyielding detailed clinical and laboratory evaluation for known etiologies of cirrhosis. All cases underwent liver biopsy which showed absence of advanced fibrosis/cirrhosis and of histological process suggesting alternate etiology, e.g. autoimmune hepatitis. None of the cases had any disease known to histopathologically mimic NCIPH, e.g. sarcoidosis, schistosomiasis. [21] .
Twenty-seven consecutive NCIPH patients were recruited for the study. The route of liver biopsy in NCIPH cases (transjugular, 18; percutaneous, 6; peroperative, 3) was decided by clinician on a case-to-case basis. In three patients, TruCut and wedge biopsies of the liver were obtained during splenorenal shunt surgery. During transjugular liver biopsy, 3 (2-9); median (range) cores of liver with size being 11 (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) mm and containing 8 (5-15) portal tracts were obtained. Similarly, during percutaneous liver biopsy 3 (2-3) cores of liver with size being 13 (8-13) mm and containing 10 (7-20) portal tracts were obtained.
The liver biopsy in these 27 patients with NCIPH showed portal fibrosis, which was mild in 17 and moderate in 2; mild peri-sinusoidal fibrosis (2) and incomplete septal cirrhosis (2) . Other liver biopsy findings in NCIPH cases were -mild sinusoidal dilatation (13) , portal vein ectasia with extension into parenchyma (8) , atretic portal venules (2) and nodular regenerative hyperplasia (1) .
Disease controls were consecutively enrolled patients with hepatitis B or C-related cirrhosis with portal hypertension, diagnosed as per radiology, laboratory and endoscopy findings. Post liver transplant patients and patients with hepatocellular malignancy were excluded. Patients with acute illness were also excluded from the study. Healthy volunteers served as healthy controls. The controls were residents from similar locality as the cases.
Besides routine clinical evaluation of study subjects, relevant laboratory evaluation was done as per case-to-case basis. Liver disease severity was assessed by Child's score. As a marker of liver fibrosis, Aspartate aminotransferase to platelet ratio index (APRI) was calculated [22] . Serum vitamin B 12 assay (normal range 200-950 pg/mL) was performed using electrochemiluminescence technique using a Roche E170 modular system. Socioeconomic class of study subjects was assessed by modified Kuppuswamy score, utilizing Indian consumer price index of August 2011, i.e. 194 [23, 24] .
Evaluation for arsenicosis
Nail arsenic level was measured as per the previously described methodology [25] . In brief, clippings from finger and/or toe nails were collected from study subject, stored in labelled polyethylene bags at 4°C till tested. After removing the dirt on their surface manually, the nails were washed using an ultrasonic bath in distilled water, and then in acetone. Overnight dried nail samples were then digested by microwave and arsenic levels measured by inductively coupled mass spectrometry. Quantitation was achieved by use of internal standards. Normal nail arsenic levels are 0.02-0.5 mg/kg of nail. Arsenic levels of >1.5 mg/kg of nail were considered high and indicative of over-exposure to arsenic in the recent past (9 months) [26] . All study cases underwent a thorough dermatological assessment for skin changes suggesting arsenicosis by a single dermatologist (RG), who was blinded to the nail arsenic levels. Skin arsenicosis was defined as typical skin lesions-hyperpigmentation and/or hypopigmentation of the unexposed body parts and/or keratosis of the palms/soles [26] .
Evaluation for thrombocytopenia associated with ADAMTS13-vWF imbalance in NCIPH patients with arsenicosis
In NCIPH patients with arsenicosis, we assessed platelet counts, plasma activity of ADAMTS13 and of vWF. ADAMTS13 activity was estimated in citrated platelet-poor plasma by an in-house collagen binding assay as previously described [11, 27, 28] . vWF activity by collagen binding was estimated in citrated plasma by a commercially available ELISA (Hyphen-Biomed #RK038A, France). Normal plasma ADAMTS13 activity was 55 % to 160 % and normal plasma vWF activity was 50 % to 150 %. vWF:ADAMTS13 ratio was calculated. A ratio of ≥3 was considered as suggesting ADAMTS13-vWF imbalance.
Statistical analysis
All discrete variables were reported as numbers (percentage) and continuous variables as median (range). Nonparametric tests were used for comparison and a p-value of <0.05 was considered as significant. The study was approved by the institutional review board and ethics committee.
Results
During August 2011-August 2013, consecutive patients attending the out-patient liver clinic fulfilling the inclusion and exclusion criteria were recruited for the study. Twenty-seven NCIPH cases and 25 portal hypertensive disease controls (hepatitis B related cirrhosis, 21; hepatitis C cirrhosis, 4) and 25 healthy controls were recruited. Demographic data of the three groups is depicted in Table 1 .
Majority of participants in all the three groups were from eastern India. Most study subjects belonged to middle and lower socioeconomic class. The monthly family income for the NCIPH cases was Rs. 10,000; Rs. 3000-Rs. 40,000 (median; range), for healthy controls was Rs. 3000; Rs. 1000-Rs. 25,000 and for disease controls was Rs. 10,000; Rs. 2000-Rs. 30,000. On interview, none of the study subjects resided next to a mining area or were on long-term complementary medications.
Baseline liver disease status in study subjects Table 2 depicts the severity of liver disease and portal hypertension in cases and disease controls. Platelet counts were similar in both the groups. Platelet counts were normal in one case and in three disease controls. There was mildmoderate thrombocytopenia (>50,000/cmm) in 12 cases and 13 disease controls and severe thrombocytopenia (<50,000/ cmm) in 14 cases and 9 disease controls. Liver disease was more severe in disease controls as compared to cases. Of the eight NCIPH patients evaluated for vWF-ADAMTS13 balance, four patients had low ADAMTS13 activity (<55 %), 6 patients had high vWF activity (>150 %) and six patients had vWF:ADAMTS13 ratio of >3. Low serum vitamin B 12 levels were noted in five (19 %) NCIPH cases as compared to nil disease control patients tested.
Arsenic levels in nails
Arsenic levels in nail clippings in cases (0.12, 0.023-2.24 mg/ kg; median, range) were similar to that in disease controls (0.15, 0.01-0.64; p-value = 0.67) and in healthy controls (0.1, 0.02-0.39; p-value = 0.74) (Fig. 1) .
Arsenic levels in the nail did not correlate with platelet count, APRI, Child's score and hepatic venous pressure gradient (HVPG) in NCIPH and disease controls (data not shown).
Two NCIPH patients (both from West Bengal) and three disease controls (all from Bangladesh) had raised (i.e. >0.5 mg/kg of nail) nail arsenic levels. One NCIPH patient, 
Skin changes of arsenicosis
Three patients with NCIPH had skin changes suggesting arsenicosis (Fig. 2a ) as compared to none amongst the disease controls nor in healthy controls (p-value = 0.2), Table 3 . These patients had predominant patchy hypo/hyper pigmentation on the trunk and punctate keratosis involving mainly the palms. One patient had extensive keratosis involving the feet as well. None of these patients had any feature suggesting psoriasis. Nail arsenic levels in these three patients with skin arsenicosis were 0.23, 0.8 and 2.24 mg/kg of nail.
Details of patients with arsenicosis
The three NCIPH cases with arsenicosis belonged to Bangladesh (n = 1) and West Bengal (n = 2). All three patients were males with age of 46 (40-54) years. One patient presented with hematemesis (managed endoscopically) and the other two patients presented with splenomegaly and hypersplenism (managed conservatively). All three patients were in Child's class A at presentation. There was no family history of similar disease in these patients. The duration of symptoms prior to presentation to our centre in these three patients was 24 months. The liver biopsy in these three patients (transjugular, 2; percutaneous, 1) showed mild portal fibrosis (2), mild sinusoidal dilation (2) and ectatic portal vein radicles (1) (Fig. 2b) . HVPG measured in 1 patient was 7 mmHg. They remain well with a follow up of 37 (34-58) months (from time of initial presentation to our centre).
The three NCIPH patients with arsenicosis were similar to the NCIPH patients without skin arsenicosis in their Fig. 1 Arsenic level, as measured by inductively coupled mass spectroscopy, in nails compared in the various study groups. The nail arsenic levels in three NCIPH patients with skin arsenicosis are marked with an asterisk (*) presentation, severity of liver disease and portal hypertension (HVPG and APRI) at presentation. The nail arsenic levels, on the other hand, were elevated in patients with skin arsenicosis (Table 4) . had raised nail arsenic level (0.8 mg/kg) and his Child's score was 6, with platelet count 60,000/cmm. He is a resident of West Bengal (India) and belongs to lower socioeconomic category (monthly family income ≤ Rs. 3000)
In the two NCIPH patients with skin arsenicosis tested, plasma ADAMTS13 activity was reduced in one patient and normal in the other (46 % and 66 %), while plasma vWF activity was increased in both patients (393 % and 257 %). vWF:ADAMTS13 ratio in these two patients was 8.54 and 3.89, respectively.
Analysis of groundwater for arsenic contamination
Two NCIPH patients with arsenicosis brought groundwater samples obtained from wells (used for drinking water) their local residential locality. The assay for arsenic levels in these samples showed 79.5 μg/L (patient from Jessore, Bangladesh, with nail arsenic level of 0.23 mg/kg of nail), and 0.9 μg/L (patient from Murshidabad, West Bengal with nail arsenic level of 0.8 mg/kg of nail), Thus, in one patient from Bangladesh, the arsenic level in drinking water was much higher than the WHO guideline of <10 μg/L and also the Indian standard of <50 μg/L. All the three patients with arsenicosis were counselled about the possible drinking water contamination with arsenic and about steps needed to rectify this.
Other associated disorders in patients with NCIPH
The other associated disorders in patients with NCIPH wereadult celiac disease (n = 3; male 2; age 29 years, 28-37 years; median, range) and systemic lupus erythematosus (n = 1; age 31 years, female). In addition, one patient had history of pre-eclampsia during prior pregnancy. One patient developed glomerulonephritis 10 years after distal splenorenal shunt surgery. 
Discussion
In this study, we demonstrate clinical (dermatological) evidence of arsenicosis was present in 11 % (3 of 27) of NCIPH patients studied, increased nail arsenic levels in 10 % (5 of 52) portal hypertensive study patients (2 NCIPH and 3 disease controls, all residents of West Bengal or Bangladesh which are plains fed by the Himalayan riversGanges and Brahmaputra) and arsenic contamination of groundwater in the residential locality of 1 NCIPH patient with arsenicosis (from Bangladesh). Our report suggests continued environmental contamination as possible cause of arsenicosis associated with portal hypertension in the second decade of the twenty-first century-reported previously from the Indian subcontinent 10-50 years ago [12] [13] [14] [15] [16] . We hypothesize that, in a predisposed individual, chronic ingestion of arsenic may lead to occlusion of the intrahepatic small branches of portal venules, as is characteristic of NCIPH [29] . In our study, histological evidence supporting portal microangiopathy was noted in liver biopsy in the 27 NCIPH patients in the form of sinusoidal dilatation, abnormal dilatation of portal venules, atretic portal venules and nodular regenerative hyperplasia. In our previous studies, we have documented low ADAMTS13 as a possible predisposition for development of NCIPH [10, 11] . It is possible that NCIPH, an example of an isolated microangiopathy affecting the liver is caused by endothelial dysfunction (low ADAMTS13 levels and high vWF levels) which can accentuate platelet adhesion to endothelium, and small vessel occlusion inside the liver by platelet microthrombi [7] . In the present report, vWF-ADAMTS13 imbalance associated with thrombocytopenia was noted in six of the eight NCIPH patients tested including the two NCIPH patients with arsenicosis (Child's score of 5 and 6). Multiple animal studies have implicated the role of oxidative stress, activation of hepatic stellate cells, enhanced apoptosis of the hepatocytes and consequent collagen deposition in arsenic induced damage of the liver [30] [31] [32] [33] . Arsenic also activates endothelium and increases vWF antigen expression on endothelial cells in vitro [34] . Mechanism of arsenic induced damage in mouse liver can be indirect by endothelial stimulation, rather than by direct cell damage [35] . We have not tested for other prothrombotic disorders in the study subjects; this is a limitation of our study.
We have observed histological evidence of NCIPH characterized by evidence of liver fibrosis/sinusoidal dilation in three portal hypertensive patients with arsenicosis diagnosed by presence of typical arsenical skin lesion [26] . Majority (90 %) of NCIPH in the current study did not have arsenicosis, clearly indicating that multiple agents can contribute to causation of NCIPH. In our study, there was no difference in liver biopsy findings and clinical presentation of NCIPH patients with or without arsenicosis.
In our study, the proportion of patients with increased nail arsenic was similar amongst NCIPH cases and in disease controls (with hepatitis B/C related cirrhosis and portal hypertension) (Table 3 ). This suggests that arsenicosis could be a cofactor in pathogenesis (for example by causing intrahepatic endothelial activation leading to platelet plugging of small blood vessels in the liver) of NCIPH as well as of other causes of portal hypertension. Wanless et al. [36] , proposed that intrahepatic microvenular occlusion contributes to development and progression of cirrhosis [36] . Whether chronic arsenic exposure can accelerate this process in patients with cirrhosis of different etiologies remains to be studied.
As per WHO criteria, we have defined arsenicosis as the presence of typical skin manifestations [26] . None of the patients had any other extrahepatic manifestations of arsenicosis like respiratory symptoms or neuropathy. Nail arsenic levels reflect exposure to arsenic over previous 3-9 months and thus may only be helpful in ongoing chronic exposure. This may not necessarily exclude chronic exposure only in the remote past [26] . In acute arsenic poisoning, urinary arsenic level gives the clue to recent ingestion of arsenic [37] .
It is likely that chronic arsenic exposure by drinking contaminated groundwater is the cause of arsenicosis in our study patients. Analysis of groundwater for arsenic levels was performed in only two patients with NCIPH and arsenicosis and not in all other study patients (this is a limitation of our study).
There are reports of increased metallic impurities, including arsenic, in complementary medicines [38, 39] . None of our study patients gave a history of long-term intake of these medications.
Groundwater contamination by arsenic in South and Southeast Asia is well-documented in Bangladesh, Eastern India (delta regions of Ganges, Brahmaputra) and Cambodia, Vietnam (Mekong delta). Arsenic leached out from sediments in Himalayan Mountains into river water undergoes microbial reduction in anaerobic conditions [40] . Public health measures in place to combat this are: identifying and marking contaminated source, shifting to safe source of water wherever possible (e.g. adequately treated surface water, rain water harvesting or alternate ground water source, increasing the depth of the well etc.), continuous education/ participation of the community and use of arsenic treatment plants/filters [41, 42] . As seen in our study, people from the poorer strata of society are still vulnerable to the effects of this environmental contamination (Fig. 2, Table 4 ). Ongoing arsenicosis in West Bengal and Bangladesh documented in this present report indicates the need to strengthen public health measures further. The 'Clean Ganges' project initiative of the Government of India, is likely to reduce environmental contamination in the Gangetic plains [43] .
It is postulated that genetic and environmental factors predispose to development of NCIPH [7] . In the past decade, few centres in India have reported decreasing incidence of NCIPH [4, 5] , this may reflect changing environmental factors in disease causation. Better sanitation and increasing use of bottled mineral water for drinking maybe some reasons for reduction of NCIPH in some parts of India. The current report on arsenicosis associated with NCIPH in patients living in areas fed by arsenic contaminated waters of Ganges-Brahmaputra rivers provides an explanation to why NCIPH is so common in India, a question asked by Professor Okuda many years ago [3] .
NCIPH is reported in patients belonging to poorer socioeconomic strata [1] . Majority (84 % to 96 %) of study subjects in this study belonged to middle or lower socioeconomic category. We have previously reported utility of low serum vitamin B 12 level as a noninvasive marker of NCIPH [44] , vitamin B 12 deficiency was seen in 19 % of NCIPH and in none of the disease controls tested. Further studies are needed to see if vitamin B 12 deficiency contributes to causation of NCIPH.
In conclusion, we demonstrate that NCIPH associated with arsenicosis, possibly from contaminated groundwater, is an ongoing problem in the Indian subcontinent in the twentyfirst century. Environmental contamination causing chronic arsenicosis and NCIPH in West Bengal, India and in Bangladesh may be considered an example of 'poverty-linked thrombophilia' causing chronic microangiopathy in the liver. 
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